Antibody-Conjugated Lipid Nanoparticles
Formulation Service
Precigenome is dedicated to driving innovation in lipid nanoparticle (LNP) technology. Building on the strength and reliability of our existing LNP services, we now offer an antibody-conjugated LNP encapsulation service designed to enhance the precision and efficiency of RNA delivery.
By combining optimized lipid formulations with targeted antibodies, this service ensures accurate payload delivery to specific sites. Whether you're engaged in genetic research, developing mRNA-based therapies, or exploring new frontiers, our targeted LNP solutions offer dependable support for your mRNA and LNP-related projects.
Antibody-conjugated lipid nanoparticles (LNPs) are advanced drug delivery systems that combine the targeting capabilities of antibodies with the encapsulation and cellular uptake properties of LNPs. This combination enhances the specificity and efficacy of drug delivery, making it particularly useful for cancer therapy, gene editing, and targeted immunotherapies.
Antibody-conjugated lipid nanoparticles represent a significant advancement in targeted drug delivery systems, combining the specificity of monoclonal antibodies with the versatile encapsulation capabilities of lipid nanoparticles. These sophisticated delivery platforms enable precise targeting of therapeutic payloads to specific cells or tissues, dramatically enhancing efficacy while minimizing off-target effects. Recent innovations in conjugation chemistry, antibody orientation strategies, and bispecific antibody approaches have addressed previous limitations and expanded potential applications across various therapeutic areas.
Benefits of Antibody-Conjugated LNP
Enhanced Targeting Efficiency
Specificity to bind cell surface receptors on target cells. Higher transfection efficiency in cancer cells and T cells.
Improved Drug Delivery Efficiency
Antibody conjugation enhances cellular uptake and intracellular stability of LNPs
Reduced Systemic Toxicity
Targeted delivery minimizes exposure to healthy tissues, lowering side effects.
Increased Therapeutic Efficacy
Ab-LNPs synergize targeting and payload delivery for superior outcomes.
Accelerate your LNP Formulation Development
In Vitro
Evaluation
Quickly screen LNP formulations for cellular uptake and viability
In Vivo
Distribution
Understand the localization of your payloads complex
Scale-up and Optimization
Leverage insights & our expertise to refine LNP formulations for scale-up studies
Target Options
Cell Targeted LNP:
CD3-Ab/LNP
CD3-Ab/LNP (CD3 antibody-conjugated lipid nanoparticles) are targeted delivery systems designed to specifically transfect T cells by leveraging anti-CD3 antibodies attached to lipid nanoparticle surfaces.
These LNPs typically incorporate ionizable lipids, cholesterol, and PEGylated lipids, with antibodies conjugated via maleimide-thiol chemistry to DSPE-PEG spacers. The anti-CD3 antibody binds to the CD3ε subunit of the T-cell receptor complex, enabling selective uptake by T cells.
CD34+ cell targeted LNP:
CD34-Ab/LNP
CD34+ cell-targeted lipid nanoparticles (CD34-Ab/LNP) are engineered delivery systems designed to specifically deliver therapeutic payloads to hematopoietic stem and progenitor cells (HSPCs) expressing the CD34 surface marker. These LNPs incorporate anti-CD34 antibodies conjugated via maleimide-thiol chemistry or similar methods to their surface, enabling receptor-mediated uptake into CD34+ cells.
The formulation typically includes ionizable lipids, PEGylated components for stability, and encapsulated nucleic acids (siRNA or mRNA) for gene editing or protein expression. By targeting CD34-a canonical HSPC marker-these LNPs enable in vivo delivery of genetic cargo without requiring stem cell mobilization or ex vivo manipulation.
Liver targeted LNP:
Tri-GalNac/LNP, 20DODAP LNP
Liver-targeted LNPs incorporating Tri-GalNAc ligands and 20DODAP lipids are specialized nanoparticles designed for hepatocyte-specific delivery by exploiting the asialoglycoprotein receptor (ASGPR) highly expressed on liver cells.
The Tri-GalNAc component-a trivalent N-acetylgalactosamine ligand-binds ASGPR with high affinity, enabling rapid receptor-mediated endocytosis. The 20DODAP lipid (likely a cationic or ionizable lipid variant) forms the nanoparticle core, facilitating encapsulation and delivery of nucleic acid payloads like siRNA or mRNA. These LNPs optimize liver specificity through ligand density and PEG-spacer engineering, balancing ASGPR engagement with avoidance of non-specific uptake.
Spleen targeted LNP:
SM10218PA LNP
Spleen-targeted SM10218PA LNP is a lipid nanoparticle formulation combining SM102 ionizable lipid with 18PA components to enhance mRNA delivery to splenic immune cells.
This formulation leverages SM102's proven mRNA encapsulation efficiency (as used in Moderna's COVID-19 vaccine) while incorporating structural modifications to improve spleen specificity. Compared to standard SM102 LNPs that primarily target the liver, SM10218PA demonstrates increased accumulation in splenic macrophages and dendritic cells, with reduced off-target effects in hepatic tissues. The "18PA" component likely refers to polyethylene glycol (PEG)-lipid modifications optimizing biodistribution, though exact structural details remain proprietary.
Lung Targeted LNP:
50DOTAP LNP, COMP3 LNP
Lung Targeted LNPs (50DOTAP LNP and COMP3 LNP) are lipid nanoparticle formulations optimized for pulmonary delivery of therapeutic payloads like mRNA. The 50DOTAP LNP incorporates 50% 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), a cationic lipid that enhances lung tropism via electrostatic interactions with negatively charged lung endothelial cells when administered intravenously. This formulation has demonstrated efficacy in delivering mRNA to treat acute respiratory distress syndrome (ARDS) and lung cancer, though high DOTAP concentrations require careful toxicity mitigation.
COMP3 LNP represents an advanced formulation designed to improve targeting specificity and safety, potentially using optimized lipid ratios or alternative cationic lipids to reduce side effects like thrombosis observed with high-DOTAP systems. Both enable precise delivery of gene editors, siRNA, or mRNA to lung tissue while minimizing off-target effects.
Applications
-
Cancer Therapy
Targeted Chemotherapy: Ab-LNPs deliver drugs like doxorubicin or PI103 to tumors via receptors (EGFR, CD47, PD-L1), achieving >300-fold higher drug-to-antibody ratios than traditional antibody-drug conjugates (ADCs). Dual-targeted LNPs enhance tumor uptake by 4–26× compared to non-targeted systems.
Immunotherapy: Bispecific LNPs co-deliver checkpoint inhibitors (e.g., anti-PD-L1) and chemotherapeutics, synergistically activating T cells while killing cancer cells.
-
Gene Therapy & mRNA Delivery
Tissue-Specific mRNA Delivery:
EGFR-targeted LNPs enable placental mRNA delivery for pregnancy-related disorders, while PD-L1-targeted systems improve transfection of quiescent T cells by 26×.
siRNA Delivery: Anti-podoplanin Ab-LNPs enhance siRNA delivery to lymphatic endothelial cells, enabling precise modulation of vascular signaling.
-
Blood-Brain Barrier Penetration
LNPs functionalized with melanotransferrin (MTf) or EGFR antibodies deliver etoposide across the blood-brain barrier, inhibiting glioblastoma growth with reduced neurotoxicity.
Some of Our Customers
